Blueprint Medicines rises after lifting AYVAKIT's FY revenue forecast

Blueprint Medicines

30/10/2024 14:27

** Shares of Blueprint Medicines  BPMC.O  rise 7.98% to
$90.06; opened at a two-month high before paring some gains 
    ** Co lifts its gastrointestinal cancer medicine AYVAKIT's
net product revenue forecast for FY24
    ** Co now expects about $475 mln to $480 mln in global
AYVAKIT net product revenues in 2024, an increase from the
previous range of $435 mln to $450 mln
    ** This updated outlook is based on continued growth in
patients on therapy, continued favorability in compliance and
other performance factors, and stronger-than-expected
performance outside of the U.S. - Co
    ** BPMC reported a Q3 pretax profit of $56.003 mln, lower
than estimates of $61 mln- LSEG
    ** Average rating on the stock is "buy" or higher; median PT
is $128 
    ** Including session's move, stock down ~3% YTD

 (Reporting by Ragini Mathur)
 ((Ragini.Mathur@thomsonreuters.com;))